Rolf Einar Engstad

Director/Miembro de la Junta en Biotec BetaGlucans AS .

65 años

Health Technology

Consumer Services

Perfil

Rolf Einar Engstad is currently the Director at Biotec BetaGlucans AS.
Previously, he worked as the Chief Scientific Officer at ArcticZymes Technologies ASA. He received his graduate and doctorate degrees from the University of Tromso.

Cargos activos de Rolf Einar Engstad

Empresas	Cargo	Inicio
Biotec BetaGlucans AS Biotec BetaGlucans AS Pharmaceuticals: MajorHealth Technology Part of Lallemand, Inc., Biotec BetaGlucans AS is a Norwegian company that specializes in developing M-Gard®, an immunomodulator that enhances the body's defense mechanisms against pathogens. The company is based in Tromsø, Norway. The technology behind M-Gard® has been successfully developed for alternative indications and applications, including nutraceuticals, wound care, and immunotherapy. The CEO of the company is Jethro Holter. Biotec BetaGlucans was acquired by Danstar Ferment AG from ArcticZymes Technologies ASA on December 31, 2020 for $7.93 million.	Director/Miembro de la Junta	-

Todos los cargos activos de Rolf Einar Engstad

Antiguos cargos conocidos de Rolf Einar Engstad.

Empresas	Cargo	Fin
ARCTICZYMES TECHNOLOGIES ASA	Director Técnico/Científico/I+D	-

Ver el detalle de la experiencia de Rolf Einar Engstad.

Formación de Rolf Einar Engstad.

University of Tromso

Doctorate Degree

Experiencias
Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Ver el detalle de la experiencia de Rolf Einar Engstad.

Relaciones

Relaciones de 1er grado

Empresas vinculadas al 1er grado

Hombre

Mujer

Administradores

Ejecutivos

Consultar la red personal

Empresas relacionadas

Empresas cotizadas	1
ARCTICZYMES TECHNOLOGIES ASA	Health Technology

Empresas privadas	1
Biotec BetaGlucans AS Biotec BetaGlucans AS Pharmaceuticals: MajorHealth Technology Part of Lallemand, Inc., Biotec BetaGlucans AS is a Norwegian company that specializes in developing M-Gard®, an immunomodulator that enhances the body's defense mechanisms against pathogens. The company is based in Tromsø, Norway. The technology behind M-Gard® has been successfully developed for alternative indications and applications, including nutraceuticals, wound care, and immunotherapy. The CEO of the company is Jethro Holter. Biotec BetaGlucans was acquired by Danstar Ferment AG from ArcticZymes Technologies ASA on December 31, 2020 for $7.93 million.	Health Technology